Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
DURHAM, N.C., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Pelthos Therapeutics Inc. ( NYSE American: PTHS ) , a biopharmaceutical company ( "Pelthos" or the "Company" ) committed to commercializing innovative therapeutic products for high unmet patient needs, today reported financial results for legacy ...
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Orchestra BioMed Holdings, Inc. ( Nasdaq: OBIO, "Orchestra BioMed" or the "Company" ) , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the ...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to persons ...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to ...
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due ...
Ligand ( LGND ) Q2 Revenue Jumps 15%
Ligand Pharmaceuticals ( NASDAQ:LGND ) , a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7, 2025. The company exceeded analyst estimates with non-GAAP EPS of $1.60 ( consensus: $1.42 ) and reported revenue ...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million ( previously $180 million - $200 million ) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 ( previously $6.00 - $6.25 )
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Medtronic ( NYSE:MDT )
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
Ligand to Report Second Quarter 2025 Financial Results on August ...
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., July 24, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m.
Why Is Pelthos Therapeutics Stock Trading Higher Thursday - Pelthos Therapeutics ( AMEX:PTHS )
Zelsuvmi cleared all molluscum lesions in 33% of patients vs. 19.7% on placebo by week 12 in 891-patient trial. Zelsuvmi is FDA-approved for at-home use in adults and children as young as one year old. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the ...
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
Ligand Partner Pelthos Therapeutics Launches ...
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - First Majestic Silver ( NYSE:AG ) , AES ( NYSE:AES )
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Verona Pharma plc VRNA rose sharply during Wednesday's session after Merck announced it will acquire the company in a $10 billion deal.
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Channel Therapeutics ( AMEX:CHRO )
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - Ligand Pharmaceuticals ( NASDAQ:LGND )
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI
Ligand to Participate in May Investor Conferences - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., May 01, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference ( Virtual ) .
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 01, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) today announced that its senior management team will participate in the following upcoming investor conferences: • H.C. Wainwright Royalty Company Conference ( Virtual ) .
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Adagio Medical Holdings ( NASDAQ:ADGM ) , Channel Therapeutics ( AMEX:CHRO )
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 450 points on Thursday. The Dow traded down 1.20% to 39,191.93 while the NASDAQ fell 0.09% to 16,293.14. However, the S&P 500 gained 0.30% to 5,291.42. Energy shares surged by 2.5% on Thursday.
Dow Falls Over 1%; US Initial Jobless Claims Decline - Adagio Medical Holdings ( NASDAQ:ADGM ) , Channel Therapeutics ( AMEX:CHRO )
U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded down 1.22% to 39,187.35 while the NASDAQ gained 0.28% to 16,352.96. The S&P 500 also rose, gaining, 0.11% to 5,281.74.
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Channel Therapeutics ( AMEX:CHRO )
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Channel Therapeutics ( AMEX:CHRO )
Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin infection affecting 16.7 million in the U.S. Feel unsure about the market's next move?
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy - Ligand Pharmaceuticals ( NASDAQ:LGND )
Stifel starts Ligand coverage with Buy rating, $43 target; cites strong royalty-financing model and biotech partnerships. Ligand posts 20%+ revenue and 35%+ EPS growth since 2022 restructure, driven by scalable platforms and lean operations. Pelosi's latest AI pick skyrocketed 169% in just one ...
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Ligand Pharmaceuticals ( NASDAQ:LGND ) , MannKind ( NASDAQ:MNKD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities analyst Joshua Dennerlein initiated coverage on MSCI Inc.
Ligandrol ( LGD-4033 ) SARMs: Ligandrol Benefits, Ligandrol Results & Buy Ligandrol Pills Alternatives Ligan 4033 By CrazyBulk
NEW YORK, April 03, 2025 ( GLOBE NEWSWIRE ) -- "We've got several pro bodybuilding athletes ready and waiting to get to know you in our free private CrazyBulk community. And you'll receive an invite to it the minute you purchase any CrazyBulk product.
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare ...
Ligand to Participate in March Investor Conferences - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., March 03, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences:
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol "PVLA" as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases ...
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol "PVLA" as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Lifecore Biomedical ( NASDAQ:LFCR )
WAYNE, Pa., Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, ...
invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology
Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute ( DFCI ) making good progress; target validation and details of mechanism of action expected in Q1 2025 Cell therapy INV441: pre-IND meeting with US FDA successfully completed.
Insider Move: Matthew E Korenberg Exercises Options, Realizing $704K At Ligand Pharmaceuticals - Ligand Pharmaceuticals ( NASDAQ:LGND )
A large exercise of company stock options by Matthew E Korenberg, President & COO at Ligand Pharmaceuticals LGND was disclosed in a new SEC filing on September 24, as part of an insider exercise. What Happened: Korenberg, President & COO at Ligand Pharmaceuticals, exercised stock options for ...
Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K - Ligand Pharmaceuticals ( NASDAQ:LGND )
On September 18, it was revealed in an SEC filing that Matthew E Korenberg, President & COO at Ligand Pharmaceuticals LGND executed a significant exercise of company stock options. What Happened: A Form 4 filing from the U.S.
Looking Into Ligand Pharmaceuticals's Recent Short Interest - Ligand Pharmaceuticals ( NASDAQ:LGND )
Ligand Pharmaceuticals's LGND short percent of float has fallen 14.7% since its last report. The company recently reported that it has 960 thousand shares sold short, which is 7.37% of all regular shares that are available for trading.
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of cardiometabolic targets Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of ...
Agenus ( AGEN ) Q2 2024 Earnings Call Transcript
AGEN earnings call for the period ending June 30, 2024.
Bristol Myers' ( BMY ) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Gilead Up as Twice-Yearly HIV Shot Prevents Infection - Gilead Sciences ( NASDAQ:GILD ) , ALX Oncology Holdings ( NASDAQ:ALXO )
Gilead Sciences, Inc. GILD announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1.
Gilead ( GILD ) Up as Twice-Yearly HIV Shot Prevents Infection
Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.
Roche ( RHHBY ) , Ascidian Team Up for RNA Exon Editing Therapeutics
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
Terns ( TERN ) Gains 13.6% YTD: Will the Momentum Continue?
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
Roche ( RHHBY ) Reports Upbeat Data on Columvi From STARGLO Study
Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.
Amgen's ( AMGN ) Blincyto Gets FDA Nod for Consolidation Treatment
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
Bristol Myers ( BMY ) Gets FDA Nod for Label Expansion of Augtyro
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Shattuck ( STTK ) Announces Positive Interim Data on Cancer Drug
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
What Makes Ligand ( LGND ) a New Strong Buy Stock
Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Compelling Reasons to Hold on to HCA Healthcare ( HCA ) Stock
HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and solid cash-generating abilities.
Why Is Ligand ( LGND ) Up 4% Since Last Earnings Report?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Buy Stocks for June 6th
HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.
